Live from AUA2025: Advances in ADT Program

CME Available: https://auau.auanet.org/content/LiveFromAUA2025#group-tabs-node-course-default1

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Pfizer, Inc.

Sumitomo Pharma America, Inc.

At the conclusion of this CME activity, participants will be able to:

1. Employ the latest AUA and NCCN guidelines (Version 1.2025) related to Androgen Deprivation Therapy (ADT) into practice

2. Evaluate clinical outcomes, efficacy, and safety profiles of different types of ADT including oral and parenteral LHRH agonists and GnRH receptor antagonists in different treatment settings.

3. Compare testosterone recovery, treatment efficacy, safety profiles, and patient preferences between different modalities of ADT.

4. Recognize common side effects associated with different types of ADT and its combination therapies as well as strategies to mitigate these adverse effects to improve patient outcomes.

5. Implement a multi-disciplinary approach in managing advanced prostate cancer with ADT.

6. Evaluate the future directions and ongoing research that may impact the use of ADT in clinical practice.